Figure 2
From: Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
Effect of gefitinib and everolimus on cell cycle progression and apoptosis in TNBC cell lines. Cells were treated for 48 h with 5 µM gefitinib (Gef) and 100 nM everolimus (Evero), as single agents and in combination (E + G). Cells were stained with propidium iodide for analysis of cell cycle (A) and annexin V-FITC for analysis of apoptosis (B). Cell cycle distribution and quantification of positive cells were evaluated by flow cytometry. Data represent the mean value ± SD of triplicate experiments. *p < 0.05; **p < 0.01 for comparison between treated cells and untreated cells (Ctlr) using Student’s t-test.
